Zobrazeno 1 - 10
of 713
pro vyhledávání: '"Hiroyuki NISHIYAMA"'
Autor:
Irfan Cicin, Elizabeth R. Plimack, Howard Gurney, Raya Leibowitz, Boris Y. Alekseev, Francis X. Parnis, Avivit Peer, Andrea Necchi, Joaquim Bellmunt, Hiroyuki Nishiyama, Jason Clark, Mihaela Munteanu, Ritesh Kataria, Calvin Jia, Thomas Powles, Cora N. Sternberg
Publikováno v:
BMC Cancer, Vol 23, Iss S1, Pp 1-11 (2024)
Abstract Background Indoleamine 2,3-dioxygenase 1 (IDO1) levels correlate with poor outcomes in urothelial carcinoma (UC). IDO1 and programmed death-ligand 1 (PD-L1) are often co-expressed. Epacadostat is a potent and highly selective inhibitor of ID
Externí odkaz:
https://doaj.org/article/263d9199baf8485699909ce6591e41d9
Autor:
Shuhei Suzuki, Yoshiyuki Nagumo, Kosuke Kojo, Atsushi Ikeda, Bunpei Isoda, Akane Yamaguchi, Kozaburo Tanuma, Satoshi Nitta, Masanobu Shiga, Takashi Kawahara, Shuya Kandori, Akio Hoshi, Hiromitsu Negoro, Bryan J. Mathis, Hiroyuki Nishiyama
Publikováno v:
Photodiagnosis and Photodynamic Therapy, Vol 51, Iss , Pp 104429- (2025)
Background: To investigate variations in diagnostic performance of photodynamic diagnosis (PDD) according to surgical experience. Methods: Data were extracted from patients having pT1 or lower primary tumors that underwent PDD-assisted transurethral
Externí odkaz:
https://doaj.org/article/bd6b3b40c22d48b1a472986cb27ac903
Autor:
Satoshi Nitta, Shuya Kandori, Kosuke Kojo, Shuhei Suzuki, Kazuki Hamada, Ichiro Chihara, Masanobu Shiga, Shotaro Sakka, Yoshiyuki Nagumo, Tomokazu Kimura, Bryan J. Mathis, Hiromitsu Negoro, Ayako Okuyama, Takahiro Higashi, Hiroyuki Nishiyama
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-6 (2024)
Abstract Background Genitourinary sarcomas are rare in adults and few large-scale studies on adult genitourinary sarcoma are reported. We aimed to elucidate the clinical characteristics, survival outcomes, and prognostic factors for overall survival
Externí odkaz:
https://doaj.org/article/6232fad35864437da3d29a89e617d15f
Autor:
Makito Miyake, Hiroshi Kitamura, Nobutaka Nishimura, Tatsuki Miyamoto, Tomonori Nakahama, Tomomi Fujii, Hiroaki Matsumoto, Hideyasu Matsuyama, Masaya Yonemori, Hideki Enokida, Rikiya Taoka, Takashi Kobayashi, Takahiro Kojima, Yoshiyuki Matsui, Naotaka Nishiyama, Hiroyuki Nishiyama, Kiyohide Fujimoto, Nishinihon Uro‐oncology Extensive Collaboration group and the Japanese Urological Oncology Group
Publikováno v:
BJUI Compass, Vol 5, Iss 2, Pp 269-280 (2024)
Abstract Objective The objective of this study is to validate the predictive ability of the 2021 European Association of Urology (EAU) risk model compared to that of existing risk models, including the 2019 EAU model and risk scoring tables of the Eu
Externí odkaz:
https://doaj.org/article/9c82631e4e444a6c8093d7f9162013b7
Autor:
Tomoyuki Koguchi, Sei Naito, Shingo Hatakeyama, Kazuyuki Numakura, Yumina Muto, Renpei Kato, Takahiro Kojima, Yoshihide Kawasaki, Kento Morozumi, Shuya Kandori, Sadafumi Kawamura, Hiroyuki Nishiyama, Akihiro Ito, Tomonori Habuchi, Wataru Obara, Chikara Ohyama, Norihiko Tsuchiya, Yoshiyuki Kojima
Publikováno v:
Cancer Medicine, Vol 12, Iss 22, Pp 20677-20689 (2023)
Abstract Objectives To investigate the efficacy of pharmacotherapy for metastatic non‐clear cell renal cell carcinoma (nccRCC) in Japanese population. Methods In this retrospective analysis, we compared the time to treatment failure (TTF) for molec
Externí odkaz:
https://doaj.org/article/5e7b3e75be6e417381a401e25356929a
Autor:
Hiroyuki Nishiyama, Yu Tanaka, Masahiro Hamada, Masahiko Ozaki, Toshihiko Minegishi, Yuichiro Ito, Shinichiroh Maekawa, Nobuyuki Yamamoto
Publikováno v:
BMC Cancer, Vol 23, Iss 1, Pp 1-11 (2023)
Abstract Background This study was conducted to identify factors associated with the safety and effectiveness of pembrolizumab in Japanese patients with unresectable urothelial carcinoma and to confirm the real-world safety and effectiveness of pembr
Externí odkaz:
https://doaj.org/article/e9e970c9534e430ba327aa4b8b5ff89f
Autor:
Bunpei Isoda, Masanobu Shiga, Shuya Kandori, Yoshiyuki Nagumo, Takayuki Yoshino, Atsushi Ikeda, Takashi Kawahara, Tomokazu Kimura, Hiromitsu Negoro, Akio Hoshi, Bryan J Mathis, Hiroyuki Nishiyama
Publikováno v:
Case Reports in Oncology, Vol 16, Iss 1, Pp 414-418 (2023)
Enfortumab vedotin (EV) is an antibody-drug conjugate and a promising agent for metastatic urothelial carcinoma (mUC). However, evaluations in end-stage renal disease patients undergoing hemodialysis are unreported. Here, we report such a case. A 74-
Externí odkaz:
https://doaj.org/article/cb161f89c008410ba2347449bc2267e9
Autor:
Ryuta Sobu, Kazuyuki Numakura, Sei Naito, Shingo Hatakeyama, Renpei Kato, Tomoyuki Koguchi, Takahiro Kojima, Yoshihide Kawasaki, Syuya Kandori, Sadafumi Kawamura, Yoichi Arai, Akihiro Ito, Hiroyuki Nishiyama, Yoshiyuki Kojima, Wataru Obara, Chikara Ohyama, Norihiko Tsuchiya, Tomonori Habuchi
Publikováno v:
Cancer Medicine, Vol 12, Iss 4, Pp 4100-4109 (2023)
Abstract It remains unknown whether the early response to vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR‐TKI) management in malignancies links to long‐term survival. The objective of this study was to investigate the
Externí odkaz:
https://doaj.org/article/24099fdcb8384362b97b3056f59518f8
Autor:
Katsuhiro Ito, Yuki Kita, Akira Yokomizo, Jun Miki, Yuko Yoshio, Hiroaki Matsumoto, Takehiko Segawa, Takashi Karashima, Naotaka Nishiyama, Kazuto Imai, Shigetaka Suekane, Seiji Nagasawa, Shin Higashi, Hiroyuki Nishiyama, Hiroshi Kitamura, Takashi Kobayashi
Publikováno v:
Cancer Medicine, Vol 12, Iss 3, Pp 2325-2332 (2023)
Abstract Pembrolizumab, an anti‐programmed death 1 monoclonal antibody, has revolutionized the treatment of metastatic urothelial carcinoma. However, the optimal treatment duration for treatment responders has not been established. To address this,
Externí odkaz:
https://doaj.org/article/8233fb43169641d5938784ae9c87acbf
Autor:
Ichiro Chihara, Hiromitsu Negoro, Jin Kono, Yoshiyuki Nagumo, Haruki Tsuchiya, Kosuke Kojo, Masanobu Shiga, Ken Tanaka, Shuya Kandori, Bryan J. Mathis, Hiroyuki Nishiyama
Publikováno v:
Communications Biology, Vol 6, Iss 1, Pp 1-11 (2023)
The diurnal rhythm of glucocorticoid is shown to be a master regulator of the bladder clock in mice.
Externí odkaz:
https://doaj.org/article/12b6b789fcba4432a4946aa21c51a836